Hypothesis: Bright dawn‑light exposure reinforces the natural trough of mTORC1 activity and the peak of mTORC2 signaling during the early fasting phase, thereby amplifying the circadian autophagy rhythm. When combined with time‑restricted feeding (TRF), this synergistic boost in mTORC2‑driven FOXO phosphorylation and ULK1 de‑phosphorylation accelerates autophagic flux, leading to improved metabolic health and reduced tumorigenesis. The effect depends on intact BMAL1, which gates nutrient‑to‑mTORC2 coupling in peripheral tissues.

Mechanistic rationale

• Dawn‑light (high‑intensity, short‑wavelength) stimulates melanopsin‑containing retinal ganglion cells, increasing sympathetic output to the suprachiasmatic nucleus (SCN). The SCN then coordinates a peripheral surge of catecholamines that transiently activate AMPK in liver and muscle, inhibiting mTORC1 via TSC2 phosphorylation during the first hours of the fasting window.
• Concurrently, light‑enhanced BMAL1/CLOCK transcriptional activity drives expression of the mTORC2‑associated protein RICTOR and the phosphatase PHLPP1, creating a permissive window for AKT‑S473 phosphorylation. Phosphorylated AKT phosphorylates FOXO1/3, promoting their nuclear export and reducing transcription of autophagy‑repressor genes, while simultaneously allowing ULK1 to remain de‑phosphorylated at mTORC1 sites, priming it for activation by AMPK.
• The resulting shift—low mTORC1, high mTORC2—extends the duration and intensity of autophagosome formation (LC3‑II conversion, p62 degradation) beyond what TRF alone achieves, enhancing clearance of damaged mitochondria and protein aggregates.
• Because mTORC2 also phosphorylates SGK1 and PKC isoforms that modulate epithelial‑to‑mesenchymal transition (EMT) signaling, its heightened activity during the fasting phase suppresses oncogenic transcriptional programs that are otherwise upregulated when mTORC1 is chronically active (e.g., by night‑time blue light).

Testable predictions

1. Mice receiving 30 min of 10,000 lux dawn‑light at ZT0 followed by a 12‑hour TRF window will show (a) increased hepatic p‑AKT(S473) and p‑SGK1(S422) levels, (b) decreased p‑S6K(T389) and p‑4EBP1(T37/46) levels during the first 6 h of fasting, and (c) elevated LC3‑II/I ratio and reduced p62 compared with TRF‑only or TRF + night‑blue‑light groups.
2. Liver‑specific BMAL1 knockout mice will abolish the dawn‑light‑induced increase in mTORC2 markers and fail to show enhanced autophagy flux, despite identical light and feeding schedules.
3. In a chemical carcinogenesis model (DEN‑induced hepatocarcinogenesis), the dawn‑light + TRF cohort will develop fewer and smaller tumors than TRF‑only controls, correlating with reduced expression of EMT markers (Vimentin, Snail) and lower phospho‑ERK1/2 levels.
4. Pharmacological inhibition of mTORC2 (e.g., with JR‑ABI‑011) during the fasting window will rescue the autophagy phenotype, confirming that the observed effects are mTORC2‑dependent.

Falsifiability If dawn‑light exposure does not alter the phosphorylation state of AKT(S473) or SGK1(S422) in peripheral tissues, or if autophagy markers (LC3‑II, p62) remain unchanged relative to TRF alone, the hypothesis is refuted. Similarly, if BMAL1 deficiency does not dampen the light‑induced mTORC2 response, the proposed gating mechanism is invalid.

Broader implication This hypothesis reframes the "civilization‑versus‑survival" dial: dawn light does not merely signal wakefulness but actively tunes the mTORC1/mTORC2 oscillatory circuit to favor a transient, organized survival state that supports cellular cleanup while restraining growth‑driven oncogenic signaling. By aligning the external light cue with the internal feeding cycle, we may harness a endogenous switch that promotes longevity without compromising tissue integrity.